RAPT Therapeutics, Inc. (NASDAQ: RAPT) related to its sale to GSK plc. Under the terms of the proposed transaction, RAPT shareholders are expected to receive $58.00 in cash for each share of RAPT common stock.
RAPT Therapeutics, Inc. (NASDAQ: RAPT) related to its sale to GSK plc. Under the terms of the proposed transaction, RAPT shareholders are expected to receive $58.00 in cash for each share of RAPT common stock.